Dr. Reddy’s Laboratories Ltd (RDY) American depository shares were barely higher pre-market Tuesday after the company said it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration.
Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials, the company said.
Angiomax is a registered trademark of The Medicines Company (MDCO).
According to The Medicines Company, Angiomax is indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of GPI and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI.
In addition, Angiomax is also indicated for use as an anticoagulant in patients with UA undergoing percutaneous transluminal coronary angioplasty (PTCA).
Angiomax is intended for use with aspirin, and is not approved for use in patients with acute coronary syndromes (ACS) not undergoing PCI or PTCA.